Hangzhou Jeci Biochem Technology Co., Ltd. is located in Hangzhou, Zhejiang Province. We are committed to sales of active pharmaceutical ingredients and pharmaceutical intermediates, cooperative R & D, custom manufacturing, sales and service as well as import of pharmaceutical raw materials.
Our company's various chemical qualifications and certificates are complete, there are a variety of pharmaceutical intermediates and precursor chemicals, and most of the common dangerous goods business qualifications, and have complete import and export qualifications, the company's products are sold all over the world, and Acting for the import and export of various products such as hazardous chemicals.
The company is mainly engaged in wholesale, retail, biological products, pharmaceutical intermediates, first-class medical equipment, petroleum products, rubber products, plastic products, biological reagents, biochemical testing reagents and consumables, chemical reagents; pharmaceutical operations (operating with valid licenses) Import and export of goods and technology (except for projects prohibited by national laws and administrative regulations, and laws and administrative regulations stipulate that projects that restrict operations can only be operated after obtaining a permit). (Projects subject to approval according to law may be operated after approval by relevant departments).
We can supply the following competitive hypoglycemic drugs. Feel free to inquire:Dipeptidyl peptidase-4 inhibitor APIs, Trelagliptin intermediates, Alogliptin intermediates, Sitagliptin intermediates, Linagliptin intermediates,Peptide APIs, Pioglitazone APIs, Gliclazide APIs, Oglimetastat intermediates
We can supply the following competitive hypoglycemic drugs. Feel free to inquire:Dipeptidyl peptidase-4 inhibitor APIs, Trelagliptin intermediates, Alogliptin intermediates, Sitagliptin intermediates, Linagliptin intermediates,Peptide APIs, Pioglitazone APIs, Gliclazide APIs, Oglimetastat intermediates
Linagliptin/Metformin Extended-Release Tablets
Recently, according to the official website of the National Medical Products Administration (NMPA), Hubei Guangchen Pharmaceutical's linagliptin/metformin extended-release tablets have been approved for marketing in China, becoming the first generic of this formulation domestically. This approval fills a gap in the Chinese market for this extended-release dosage form and is expected to provide type 2 diabetes patients with a more convenient treatment option.
Linagliptin/metformin extended-release tablets are a combination antidiabetic drug marketed under the brand name Jentadueto® XR. Developed by Boehringer Ingelheim, it was approved by the U.S. FDA in May 2016.
From a mechanism-of-action perspective, this fixed-dose combination incorporates two antidiabetic agents with distinct mechanisms. Linagliptin belongs to the DPP-4 inhibitor class; it controls blood glucose levels by increasing substances in the body that stimulate the pancreas to release more insulin, while also signaling the liver to stop producing glucose when blood sugar is too high. Metformin works by reducing intestinal absorption of sugar, decreasing the liver's release of stored glucose, and helping the body utilize glucose more effectively.
Jentadueto® XR is available in two strengths-5 mg/1000 mg and 2.5 mg/1000 mg-and is taken once daily, greatly improving patient convenience. However, this extended-release combination had yet to be launched in China, leaving a notable market gap.
Although the extended-release version was absent, the "golden pairing" of linagliptin and metformin was already well known in China. Currently, the linagliptin/metformin conventional tablet is available on the domestic market.
The originator product, Boehringer Ingelheim's "Eucreas," entered China as early as 2017. Subsequently, generic versions from domestic pharmaceutical companies such as Dongyangguang, Qilu Pharmaceutical, and Huahai Pharmaceutical were successively approved, creating a competitive landscape. According to the PharmaCube Data All-Terminal Sales Analysis System, sales of this product in China exceeded RMB 100 million in 2024, representing a staggering 400% year-on-year increase and indicating explosive growth.
Source: Yaozhi Data Enterprise Edition - Pharmaceutical Full-Channel Sales Analysis System
As an important segment of the domestic pharmaceutical market, the diabetes medication sector has maintained steady growth. Hubei Guangchen Pharmaceutical's entry comes at a time of rapid market expansion. As the first generic company for the extended-release formulation, the firm is well positioned to gain a foothold in the competition by leveraging the advantages of this dosage form.
